{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:51:42Z","timestamp":1789865502125,"version":"4.0.1"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 6% of patients with thalassemia receiving deferiprone develop neutropenia. Present practice is to monitor absolute neutrophil count (<jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content>) weekly and to interrupt treatment at the first sign of neutropenia, lest continuation lead to progressive neutrophil reduction. In a 6\u2010month study evaluating the safety and efficacy of a liquid form of deferiprone in 100 children, <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> was initially checked weekly for all patients. For individuals experiencing mild neutropenia, deferiprone was continued but monitoring was increased to daily until resolution. Therapy was to be suspended only if the episode was prolonged or if it worsened. Four patients experienced single episodes of mild neutropenia, and two others each experienced two episodes. All eight episodes resolved within 4\u20137\u00a0d despite continued therapy. (One patient later developed agranulocytosis and had treatment terminated.) This study showed that not all cases of mild neutropenia during deferiprone therapy develop into agranulocytosis, and suggests that many may not be caused by deferiprone. Transient declines in <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> to levels defined as neutropenic are common even in healthy individuals, particularly children; and it could be that the frequent monitoring of <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> mandated during deferiprone therapy may reveal cases of transient neutropenia that would otherwise have gone undetected and resolved on their own without clinical consequences. In patients with thalassemia, several factors increase the probability of a transient fall in <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content>. These findings raise the question of whether deferiprone should be routinely stopped in cases of mild neutropenia, provided that such patients have their <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> monitored more frequently during the neutropenic episode.<\/jats:p>","DOI":"10.1111\/ejh.12241","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T15:18:00Z","timestamp":1387034280000},"page":"337-340","source":"Crossref","is-referenced-by-count":18,"title":["Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count"],"prefix":"10.1111","volume":"92","author":[{"given":"Amal M.","family":"El\u2010Beshlawy","sequence":"first","affiliation":[{"name":"Hematology Department Pediatric Hospital Cairo University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen S.","family":"El\u2010Alfy","sequence":"additional","affiliation":[{"name":"Children Hospital Ain Shams University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teny T.","family":"Sari","sequence":"additional","affiliation":[{"name":"Cipto Mangunkusumo Hospital Jakarta Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee L.","family":"Chan","sequence":"additional","affiliation":[{"name":"University of Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tricta","sequence":"additional","affiliation":[{"name":"ApoPharma Inc. Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,30]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.07.012"},{"key":"e_1_2_3_3_1","unstructured":"Ferriprox\u00ae (Deferiprone) Summary of Product Characteristics (SmPC).http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h108.htm."},{"key":"e_1_2_3_4_1","unstructured":"BertolaU CollellM PigaA ViscontiRM CohenA.Neutropenia in homozygous b\u2010thalassemic patients on desferrioxamine (DFO) treatment. In:Proceedings of the 8th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases Corfu Greece:1997:90."},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0f13"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3280"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2002.31919"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-065805"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11132-9"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12241","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:11:49Z","timestamp":1695553909000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,30]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/ejh.12241"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12241","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,30]]}}}